Tissue Repair & Regenerative · Combination

BPC-157 + TB-500 Synergy

For Research Use Only. Not for Human or Veterinary Use.

Overview

Pairing BPC-157 with TB-500 (Thymosin Beta-4 / Ac-SDKP) is a complementary-peptide strategy studied in regenerative research. The two act through different but overlapping routes — BPC-157 chiefly via nitric-oxide modulation and angiogenic growth-factor signalling, TB-500 via actin sequestration and cell migration — so the combination is investigated as a broader repair stimulus than either alone. This page compares the two and summarises the research rationale for using them together.

Overview

The two peptides address different parts of the repair process. The table below summarises how they are usually positioned relative to each other.

PeptidePrimary mechanismTissue focus
BPC-157NO modulation, VEGF/FGF upregulation, gastroprotectionGI tract, tendon, nerve
TB-500 (Ac-SDKP)Actin sequestration, angiogenesis, ECM remodelingMuscle, skin, cardiac
CombinationComplementary angiogenic + cytoprotectiveMulti-tissue repair research

Mechanisms of Synergy

Complementary angiogenesis

BPC-157 is studied for raising VEGF/FGF via NO-dependent routes, while TB-500 is studied for directly promoting endothelial-cell migration — two different angles on new-vessel formation.

Coordinated cell migration

BPC-157 is linked to fibroblast/keratinocyte migration; TB-500 supplies the actin dynamics cells need to move — together studied for more efficient wound repopulation.

Balanced inflammation

Both are reported to lower pro-inflammatory cytokines and support anti-inflammatory mediators, studied for resolving the inflammatory phase without over-suppressing it.

Matrix remodeling

BPC-157 is associated with collagen synthesis and TB-500 with MMP modulation — a combination framed around scar quality and tensile strength.

Comparative Properties

PropertyBPC-157TB-500 (Ac-SDKP)
Molecular weight1419.5 Da500.5 Da
Amino acids154 (active fragment)
Half-life≈ 15 min (plasma)≈ 2–6 h
CharacterHydrophilic (logP −2.8)Hydrophilic (logP −3.1)
Primary mechanismNO modulation, VEGF/FGFActin sequestration, migration
Stability (lyophilized)≥ 24 months at −20°C≥ 24 months at −20°C

Synthesis Pathway Comparison

Both peptides are made separately by Fmoc solid-phase peptide synthesis and purified to research grade; TB-500 (Ac-SDKP) additionally carries an N-terminal acetyl group.

ParameterBPC-157TB-500 (Ac-SDKP)
MethodFmoc-SPPSFmoc-SPPS
ResinRink amide MBHARink amide MBHA
N-terminal modificationFree amineAcetylated (Ac)
Amino acids15 residues4 residues (active fragment)
CouplingHBTU / HOBt / DIPEAHBTU / HOBt / DIPEA
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)TFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18)Preparative RP-HPLC (C18)
Salt formTrifluoroacetate / chlorideTrifluoroacetate / chloride

Stability & Compatibility

The two peptides have different degradation kinetics, so the usual research recommendation is to reconstitute and store them separately.

ParameterGuidance
Storage formStore each peptide separately in sealed vials at −20°C
Co-formulationNot recommended in the same vial (different kinetics)
CombiningIf co-injection is intended, combine only immediately before use
AdministrationBest given as separate injections at different sites
pH compatibilityBoth work near pH 5.5–6.5 — compatible range
Freeze–thawLimit to ~3 cycles; aliquot if needed

Research Evidence

Combination research is mostly at the animal-model stage. Representative models and their focus are named below; specific numerical outcomes are not restated here as claims.

ModelResearch focus
Rodent skin-excision woundCombined vs single-peptide wound closure
Rat Achilles-tendon transectionFunctional and histological tendon recovery
Rat muscle-crush injuryMuscle-fiber regeneration and fibrosis
Murine full-thickness burnEpithelialization rate

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Research Combination Protocol

Reconstitution-oriented reference from the literature; not human dosing guidance.

ParameterBPC-157TB-500
Individual research dose≈ 250–500 µg≈ 2.5–5 mg
FrequencyDaily (study protocols)≈ every 72 h
RouteSubcutaneousSubcutaneous (separate site)
ReconstitutionBacteriostatic waterBacteriostatic water

Safety (Combination)

Both peptides are individually reported as well tolerated in animal studies, with no specific interaction documented; the combination is nonetheless for research use only, not for human or veterinary use.

  • Administer as separate injections at different sites rather than mixing in one vial.
  • Follow the same handling and storage precautions as for each peptide alone.

Selected References

  • Sikiric P, et al. BPC-157 tissue-repair literature (review and preclinical studies).
  • Malinda KM, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
  • Goldstein AL, Kleinman HK. Advances in the applications of thymosin beta-4 (review literature).

Quality & Supply

  • Both peptides available research-grade, HPLC-characterized with a Certificate of Analysis
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Supplied as separate vials for flexible research protocols

Need BPC-157 + TB-500 Synergy — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote